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Abstract
The Aurora kinase family (Aurora A, B and C) are crucial regulators of several mitotic events, including cytokinesis.
Increased expression of these kinases is associated with tumorigenesis and several compounds targeting Aurora kinase
are under evaluation in clinical trials (a.o. AT9283, AZD1152, Danusertib, MLN8054). Here, we demonstrate that the pan-
Aurora kinase inhibitor Tozasertib (VX-680 and MK-0457) not only causes cytokinesis defects through Aurora kinase
inhibition, but is also a potent inhibitor of necroptosis, a cell death process regulated and executed by the RIPK1, RIPK3
and MLKL signalling axis. Tozasertib’s potency to inhibit RIPK1-dependent necroptosis and to block cytokinesis in cells
is in the same concentration range, with an IC50 of 1.06 µM and 0.554 µM, respectively. A structure activity relationship
(SAR) analysis of 67 Tozasertib analogues, modiﬁed at 4 different positions, allowed the identiﬁcation of analogues that
showed increased speciﬁcity for either cytokinesis inhibition or for necroptosis inhibition, reﬂecting more speciﬁc
inhibition of Aurora kinase or RIPK1, respectively. These results also suggested that RIPK1 and Aurora kinases are
functionally non-interacting targets of Tozasertib and its analogues. Indeed, more speciﬁc Aurora kinase inhibitors did
not show any effect in necroptosis and Necrostatin-1s treatment did not result in cytokinesis defects, demonstrating
that both cellular processes are not interrelated. Finally, Tozasertib inhibited recombinant human RIPK1, human Aurora
A and human Aurora B kinase activity, but not RIPK3. The potency ranking of the newly derived Tozasertib analogues
and their speciﬁcity proﬁle, as observed in cellular assays, coincide with ADP-Glo recombinant kinase activity assays.
Overall, we show that Tozasertib not only targets Aurora kinases but also RIPK1 independently, and that we could
generate analogues with increased selectivity to RIPK1 or Aurora kinases, respectively.
Introduction
Mitosis is a multi-step process that is tightly regulated
by several classes of kinases, like cyclin-dependent kinases
(CDKs) and Aurora kinases1. The Aurora serine/threo-
nine kinase family consists of three kinases in mammals:
Aurora A, Aurora B and Aurora C2. All three Aurora
kinases, although being structurally similar, have different
functions and cellular localisations during mitosis2–5.
Aurora A and B are expressed in most cell types and play
important roles in centrosome maturation, mitotic spin-
dle formation, kinetochore assembly and cytokinesis, the
ﬁnal step of cell division2,6,7. Aurora C, in contrast, is only
expressed in testis where it is crucial for spermatogen-
esis2. Aurora A and B have been described as oncogenes
and increased expression or polymorphisms of these
kinases have been observed in several types of cancer6,
like breast cancer8,9, prostate cancer10,11 and non-small-
cell lung carcinoma12. Inhibition of Aurora kinase results
in failure of G2/M transition, abnormal spindle formation
leading to cytokinesis defects and apoptosis13. Several
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Aurora kinase inhibitors have been developed, like
MLN8054 and MLN8273, which are currently in clinical
trials phase I and phase II for the treatment of solid
tumours and hematopoietic cancers5,6. In this paper, we
will focus on the pan-Aurora kinase inhibitor Tozasertib
(VX-680, MK-0457), which has been described as a type I
small molecule inhibitor that targets the ATP-binding
pocket of Aurora kinases14. Tozasertib retards tumour
growth in xenograft models (a.o. HL-60 and
HCT116)2,3,15 and was in clinical trial phase II for solid
tumours and leukaemia5,6. Although Tozasertib treatment
has clear anti-tumour activity, studies were discontinued
due to toxic adverse effects5,16. In a broad spectrum drug/
kinome-binding study, it was reported that Tozasertib can
bind to receptor-interacting-protein kinase 1 (RIPK1)
with a Kd of 20 nM
17, while the Kd value is 0.6 nM for
binding to Aurora A15. RIPK1 is part of the receptor-
interacting-protein kinase family that is involved in the
regulation of cell death processes and inﬂammation18–21.
Reports are also emerging of its involvement in tumor-
igenesis22,23. Necroptosis is a cell death process regulated
by a kinase signalling cascade in the absence of caspase
activation18,21,24–26. TNF-induced necroptosis involves
activation of RIPK1 and RIPK3 in a necrosome complex,
leading to the activation of the execution protein-mixed
lineage kinase domain-like protein (MLKL)18,20,27–29.
Here, we characterise Tozasertib as cytokinesis and
necroptosis inhibitor in a cellular model system, simul-
taneously analysing multiple image-based parameters
reﬂecting these phenotypes. A screening of 67 novel
Tozasertib analogues suggests that both pathways are
independent from each other and that analogues can be
identiﬁed that have a higher selectivity for either cellular
response.
Results
Tozasertib induces cytokinesis defects and inhibits
necroptosis at similar dose dependency
Since Tozasertib is a pan-Aurora kinase inhibitor14, we
used the well-established L929 cellular model for TNF-
induced necroptosis research30 to conﬁrm inhibitory
effects of Tozasertib on cell growth and cytokinesis and to
evaluate its effect on cell death. Tozasertib is not toxic on
itself in murine L929sAhFas cells at 10 µM or lower
(Supplementary Figure 1B), but impairs colony formation
in a clonogenic assay from 0.2 µM on (Fig. 1a), illustrating
its cytostatic activity. Also, the total number of nuclei per
image frame decreased with increasing concentration of
Tozasertib (Fig. 1b), reﬂecting Tozasertib-induced growth
arrest (IC50 value of 0.122 µM). Tozasertib-induced
inhibition of autophosphorylation of endogenous Aurora
A (Aur A) and B (Aur B) conﬁrms that both Aurora
kinases are targeted in L929sAhFas cells (Fig. 1c). Using
high-content imaging, not only the number of nuclei, but
also the nuclear morphology can be assessed31. Both
nuclear area and nuclear roundness were analysed as
parameter for cytokinesis defects (Fig. 1d–e). With
increasing concentration of Tozasertib, nuclear area
increased (mean increase to 250 µm2 at highest con-
centration) and nuclear roundness decreased (mean
decrease to 0.80) (Fig. 1d–e). The parameter nuclear area
showed a linear correlation with the number of cells or
cell growth in function of the concentration of Tozasertib
(Fig. 1f). Therefore, cell number and nuclear area will be
further used to evaluate cytokinesis inhibition, a
(see ﬁgure on previous page)
Fig. 1 Tozasertib induces cytokinesis defects and inhibits necroptosis with similar dose dependency. a L929sAhFas cells were treated with
Tozasertib (concentration as indicated) for 24 h. Then, a clonogenic assay was performed to determine colony-forming capacity. Quantiﬁcation was
performed using ImageJ. Data represent mean values ±S.E.M. (n = 3). b, d-f L929sAhFas cells were treated with DMSO (control) or Tozasertib (Toz)
(concentrations as indicated) for 24 h (f) or 48 h (b, d–e). Cells were stained with Hoechst (1 µM) and high-content images were acquired using BD
pathway Bio-imager and analysed using ColumbusTM software. The dotted control line indicates the real y-axis value corresponding to a normal
nucleus (DMSO treatment). Data represent mean values ±S.E.M., n = 6. Nuclear roundness is quantiﬁed as with 0 being a straight line and 1 being a
perfect circle. Number of nuclei was plotted against the nuclear area (µm2) for all replicates (n = 6). Linear relation between parameters was shown
using GraphPad Prism 7. c L929sAhFas cells were treated with DMSO or Tozasertib (10 µM) for 16 h, lysed and immunoblotted with the indicated
antibodies. g–I L929sAhFas cells were pre-treated with DMSO (control), Nec1s (3 µM) or Tozasertib (3 µM) (g) or with concentrations as indicated (h-i)
for 1 h, followed by mTNF (20 ng/mL) (g, h) (n = 4) or mTNF (20 ng/mL) + zVAD.fmk (20 µM) (i) stimulation (n = 3). * = Signiﬁcance compared to
DMSO, Δ = signiﬁcance compared to Nec-1s. (see 'Material and methods' for statistical analysis) j MEF cells were pre-treated with DMSO, Nec-1s or
Tozasertib (concentration as indicated) for 1 h, followed by stimulation with hTNF (20 ng/mL) + Tak1i (1 µM) + zVAD.fmk (20 µM) for 4 h (n = 3). k MEF
(n = 3) and L929sAhFas (n = 3) cells were pre-treated with DMSO (control), Nec1s (10 µM) or Tozasertib (10 µM) for 1 h, followed by stimulation with
agonistic anti-Fas antibody (250 ng/mL) or hTNF (20 ng/mL) + Tak1i (1 µM), respectively. One-way ANOVA was performed using Tukey correction for
multiple comparison (compared to DMSO control). l HT-29 cells were pre-treated with DMSO, Nec1s or Tozasertib (concentration as indicated) for 1 h,
followed by stimulation with hTNF (100 ng/mL) + Tak1i (1 µM) + zVAD.fmk (20 µM) for 16 h. g, l Cells were stained with SytoxGreen (5 µM) and cell
death was followed over time using the FluoStar ﬂuorescence detection system. h–k Cells were stained with propidium iodide (PI) (3 µM) and
Hoechst (1 µM) for image analysis with BD pathway. Cell death percentage (% PI-positive nuclei) was calculated as percent of control. Data represent
mean values ±S.E.M. (g–l). The time kinetic experiment (g) was statistically analysed using repeated measurements data analysis and dose responses
(IC50 determination) analysed using probit analysis (see 'Material and methods')
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consequence of Aurora kinase inhibition5–7 (Fig. 1f). Next,
Tozasertib was tested in murine (L929sAhFas, MEF) and
human (HT29) cells for inhibition of RIPK1-dependent
necroptosis. Indeed, Tozasertib (3 µM) protects against
TNF-induced RIPK1-dependent necroptosis over time in
L929sAhFas cells (Fig. 1g). This protection is dose
dependent with an IC50 value of 0.55 µM (Fig. 1h and
Table 1). Although Necrostatin-1s (Nec1s) protects
against RIPK1-dependent cell death (Fig. 1g–l), RIPK1
inhibition by Nec1s does not result in cytokinesis defects
(Supplementary Figure 2). Also, treatment with GSK’963,
a more potent and selective RIPK1 inhibitor than Nec-
1s32, did not affect cytokinesis in L929sAhFas cells
(Supplementary Figure 2), suggesting that RIPK1 kinase
activity is not involved in cytokinesis. In sensitising con-
ditions in L929sAhFas cells (mTNF+zVAD.fmk) and in
MEF cells, Tozasertib protects against cell death with an
IC50 of 1.08 µM (Fig. 1i and Table 1) and 2.56 µM (Fig. 1j
and Table 1), respectively. Although Tozasertib inhibits
RIPK1-dependent apoptosis in MEF cells, its inhibition on
RIPK1-dependent necroptosis in the same cells is
remarkably less effective (Fig. 1j, k). This suggests that
RIPK1 kinase engagement might be different in apoptotic
and necroptotic conditions. In the case of induction of
RIPK1-independent apoptosis in L929sAhFas cells by
agonistic anti-Fas antibody, no inhibition is observed
(Fig. 1k). This indicates that Tozasertib does not affect
Fas-mediated apoptosis at the level of FADD/caspase-8
activation, cytochrome c release or the Apaf-1-mediated
caspase cascade. Finally, Tozasertib also blocks RIPK1-
dependent necroptosis in the human HT29 cell line with
an IC50 of 0.26 µM (Fig. 1l and Table 1). Both in sensi-
tising necroptosis conditions in L929sAhFas cells (mTNF
+zVAD.fmk) (Supplementary Figure 3A) and in HT29
cells (hTNF+Tak1i+zVAD.fmk) (Supplementary Fig-
ure 3B), the protective effect of Tozasertib is partially lost
at 10 µM and was excluded for IC50 determination.
Overall, Tozasertib-induced growth arrest (IC50 0.97
µM), cytokinesis inhibition (IC50 1.06 µM) and necrop-
tosis inhibition (IC50 0.55 µM) show similar dose
dependency in different cellular models (Table 1).
Tozasertib-induced cytokinesis defects and necroptosis
inhibition are not correlated
Previous results with Nec1s and GSK’963 suggested that
RIPK1 is not involved in cytokinesis (Supplementary
Figure 2). In order to further investigate whether Aurora
kinase-dependent cytokinesis and RIPK1-dependent
necroptosis are interrelated, a small panel of pan-
Aurora kinase inhibitors were tested for their ability to
inhibit necroptosis in L929sAhFas cells (Table 2). This
panel included Tozasertib, Barasertib (more speciﬁc for
Aurora B), AMG-900, Danusertib and SNS-314 mesylate.
Of all Aurora kinase inhibitors tested, only Tozasertib andTa
b
le
1
To
za
se
rt
ib
in
d
uc
es
cy
to
ki
n
es
is
d
ef
ec
ts
an
d
in
h
ib
it
s
n
ec
ro
p
to
si
s
w
it
h
si
m
ila
r
p
ot
en
cy
,
w
h
ile
N
ec
1s
in
h
ib
it
s
n
ec
ro
p
to
si
s
w
it
h
ou
t
af
fe
ct
in
g
cy
to
ki
n
es
is
To
za
se
rt
ib
N
ec
-1
s
C
om
p
ou
nd
(p
re
)t
re
at
m
en
t
ti
m
e
(h
)
N
ec
ro
p
to
si
s
tr
ea
tm
en
t
ti
m
e
(h
)
IC
50
(µ
M
)
95
%
C
I
(µ
M
)
IC
50
(µ
M
)
95
%
C
I
(µ
M
)
C
yt
ok
in
es
is
C
lo
no
ge
ni
ci
ty
24
–
0.
12
2
0.
10
4–
0.
13
9
N
T
N
T
C
el
lg
ro
w
th
48
–
0.
96
9
0.
91
5–
1.
02
5
N
C
N
C
N
uc
le
ar
ar
ea
!
48
–
1.
05
6
1.
01
3–
1.
10
1
N
C
N
C
N
uc
le
ar
ro
un
dn
es
s
48
–
1.
63
9
1.
52
1–
1.
84
2
N
C
N
C
N
ec
ro
pt
os
is
L9
29
-m
TN
F
1
5
0.
55
4Δ
Δ
Δ
0.
48
3–
0.
63
5
0.
14
9
0.
12
6–
0.
17
4
L9
29
-m
TN
F+
zV
A
D
1
3
1.
08
2Δ
Δ
Δ
0.
92
3–
1.
27
7
0.
24
0.
21
0–
0.
27
5
M
EF
-h
TN
F+
TA
K1
i+
zV
A
D
1
4
2.
56
1Δ
Δ
Δ
2.
23
7–
2.
93
4
0.
80
3
0.
70
3–
0.
91
4
H
T2
9-
hT
N
F+
TA
K1
i+
zV
A
D
1
16
0.
25
7Δ
Δ
Δ
0.
22
7–
0.
29
1
0.
07
7
0.
06
7–
0.
09
0
C
ha
ra
ct
er
is
at
io
n
an
d
qu
an
tiﬁ
ca
tio
n
of
To
za
se
rt
ib
an
d
N
ec
1s
af
fe
ct
in
g
cy
to
ki
ne
si
s
(c
lo
no
ge
ni
ci
ty
,c
el
lg
ro
w
th
,n
uc
le
ar
ar
ea
an
d
nu
cl
ea
r
ro
un
dn
es
s
as
pa
ra
m
et
er
s)
an
d
ne
cr
op
to
si
s
(L
92
9,
M
EF
an
d
H
T2
9
ce
ll
lin
es
as
m
od
el
sy
st
em
s)
.I
C
50
va
lu
es
w
er
e
ca
lc
ul
at
ed
an
d
co
m
pa
re
d
us
in
g
do
se
-r
es
po
ns
e
cu
rv
es
of
th
re
e
in
de
pe
nd
en
t
ex
pe
rim
en
ts
an
d
Pr
ob
it
an
al
ys
is
(s
ee
'M
at
er
ia
l
an
d
m
et
ho
ds
').
Th
e
95
%
co
nﬁ
de
nc
e
in
te
rv
al
s
(C
I)
fo
r
IC
50
s
ar
e
al
so
in
di
ca
te
d
N
T
no
t
te
st
ed
,N
C
no
t
ca
lc
ul
ab
le
!
va
lu
es
re
pr
es
en
t
EC
50
,Δ
re
fe
rs
to
th
e
si
gn
iﬁ
ca
nc
e
of
th
e
di
ff
er
en
ce
re
la
tiv
e
to
th
e
IC
50
of
N
ec
-1
s
Martens et al. Cell Death and Disease  (2018) 9:211 Page 4 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
SNS-314 mesylate were able to inhibit necroptosis with
IC50 values of 1.1 µM and 0.4 µM, respectively (Table 2).
AMG-900 inhibits cytokinesis with an IC50 in nanomolar
range (nuclear area) but cannot inhibit necroptosis
(Table 2). These results suggest that cytokinesis and
necroptosis are independent processes.
Dissection of cytokinesis inhibition and necroptosis
inhibition by SAR of Tozasertib analogues
In order to analyse the required chemical structures that
deﬁne induction of cytokinesis and necroptosis inhibition
in more detail and to design therapeutic Tozasertib ana-
logues that would target RIPK1 with high speciﬁcity and
potency, 67 Tozasertib analogues were developed (Hof-
mans S. et al., manuscript under review) and tested for
both cytokinesis and necroptosis inhibition (PI positivity
with both 0.5 h and 24 h pre-treatment) (Fig. 2). These
analogues were designed by changing 4 different positions
of Tozasertib (Fig. 2a, Hofmans S. et al., manuscript under
review). Scatter plots of cell growth or nuclear area in
relation to the necroptosis-inhibiting capacity indicate
that Tozasertib inhibits both cellular processes (Fig. 2b, c).
Several Tozasertib analogues lose their potency to inhibit
these cellular processes, while others preferably still
inhibit cytokinesis and proliferation without affecting
necroptosis (UAMC2550 and UAMC3033), or vice versa
(UAMC3062, UAMC3063 and UAMC3064) (Fig. 2b, c).
Also, the Aurora A inhibitor MLN-8054 was included in
the screening as benchmark of cytokinesis inhibition
without affecting RIPK1-dependent cell death (Fig. 2b, c).
These data conﬁrm the previous results (Table 2) that
Aurora kinase inhibition has no contribution to the
necroptosis inhibition. All necroptosis inhibitors have
been validated using a kinetic cell death assay (Fig. 2d)33.
Both after mTNF and mTNF+zVAD.fmk (sensitising
condition) stimulation in L929sAhFas cells, a similar
ranking of the Tozasertib analogues was obtained, with
UAMC3062, UAMC3063 and UAMC3064 being more
potent necroptosis inhibitors than Tozasertib (Fig. 2d, e).
Although analogues were identiﬁed with better speciﬁcity
to necroptosis inhibition compared to Tozasertib, they
were not more efﬁcient than Nec1s (Fig. 2d, e). Next,
hierarchical clustering of all analogues using cytokinesis
and cell death IC50 values resulted in the identiﬁcation of
different classes of Tozasertib analogues (Fig. 2f). This
Ward’s method clustering identiﬁed analogues with
increased selectivity for one or the other phenotype
(Fig. 2f). Compared to Tozasertib, the analogues
UAMC3062, UAMC3063 and UAMC3064 were more
selective for necroptosis protection and UAMC3033 and
UAMC2550 were more selective for cytokinesis defects
(Fig. 2f and Supplementary Figure 4). Overall, based on
the characterisation of the cellular phenotypes, analogues
were identiﬁed with higher selectivity to either AuroraTa
b
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kinases or RIPK1 but not higher potency compared to
Tozasertib and Nec1s, respectively.
Potency and speciﬁcity ranking of Tozasertib analogues is
conﬁrmed by in vitro kinase activity proﬁling and validated
in a human and mouse cell line
Since all data so far suggested that Tozasertib is a RIPK1
inhibitor and Tozasertib was shown to bind to RIPK117,
we performed ADP-Glo kinase activity assays using
recombinant hRIPK1, hAurora A (hAur A) and hAurora
B (hAur B) (Fig. 3a–c). In order to conﬁrm speciﬁcity,
IC50 values were determined for all three recombinant
kinases. Indeed, Tozasertib inhibits hAur A and hAur B
kinase activity with an IC50 value of 0.030 µM and 0.068
µM, respectively, but it also inhibits hRIPK1 kinase
activity with an IC50 of 0.18 µM (Fig. 3a–c and Supple-
mentary Table 1). Inhibition of necroptosis by Tozasertib
seems to act speciﬁcally through RIPK1 inhibition, since
Tozasertib is not able to inhibit recombinant mRIPK3
kinase activity (Supplementary Figure 5). Although IC50
values for the cellular phenotypes were similar, the IC50
values for inhibition of recombinant kinase activity differs
between the Aurora kinases and RIPK1 (Table 1 and
Fig. 3a–c). The analogues that showed proliferation and
cytokinesis defects without inhibition of necroptosis
(UAMC3033 and UAMC2550) inhibit hAur A and hAur
B kinase activity, albeit with lower potency than Toza-
sertib (IC50s between 0.2 and 0.4 µM), whereas limited
inhibition of hRIPK1 kinase activity is observed (Fig. 3a–c
and Supplementary Table 1). On the other hand, the
analogues with higher speciﬁcity for necroptosis inhibi-
tion compared to Tozasertib (UAMC3063 and
UAMC3064) could inhibit hRIPK1 kinase activity with a
similar dose response as Tozasertib. Although no
cytokinesis and proliferation defects were detected based
on the cellular parameters analysed, these analogues are
still able to inhibit hAur A and hAur B kinase activity,
albeit with a >10-times lower potency than Tozasertib
(Fig. 3a–c and Supplementary Table 1). Due to redun-
dancy in the function of Aurora A and B, loss in potency
of both Aurora A and B inhibition, may give rise to the
more speciﬁc cell death phenotype for these analogues.
Also, for Aurora kinase inhibition, IC50 values between
recombinant kinase assays and cellular phenotypes differ
signiﬁcantly from nanomolar range for the recombinant
kinase assays to micromolar range for cellular phenotypes
(Table 1 and Supplementary Table 1). This may be due to
timing and parameter chosen for the cellular assay, or to
poor membrane permeability. Therefore, small changes in
the enzymatic IC50 values could result in signiﬁcant
changes in cellular phenotype. Nec1s only inhibits
recombinant hRIPK1 and the inactive analogue
UAMC3132 lost the ability to inhibit all three recombi-
nant proteins (Fig. 3a–c). Overall, these data indicate that
the inhibition of Aurora kinases and RIPK1 by Tozasertib
and its analogues is correlated to the proliferation and
cytokinesis defects and necroptosis protection,
respectively.
In a ﬁnal step, the selected analogues with increased
speciﬁcity were also tested in a cell death assay in the
human HT29 (Fig. 3d) and the mouse L929sAhFas
(Fig. 3e) cell lines (sensitised condition). After stimulation
with hTNF+Tak1i+zVAD.fmk to induce necroptosis in
HT29, UAMC3063-UAMC3064 could protect with
similar IC50 values as Tozasertib (0.1–0.2 µM), while
UAMC2550-UAMC3033 (more speciﬁc for Aurora
kinase) and the inactive analogue UAMC3132 could not
protect (Fig. 3d and Supplementary Table 2). Similar
(see ﬁgure on previous page)
Fig. 2 Dissection of cytokinesis inhibition and necroptosis inhibition by SAR of Tozasertib analogues. a Structure of Tozasertib and an
illustration of the four different positions that have been altered to the molecule resulting in 67 Tozasertib analogues (aliphatic substituents (R1),
pyrazole moieties (R2), cyclohexyl moieties (R3) and S<>N linker (X)). b–c The 67 Tozasertib analogues were screened for both cytokinesis defects and
inhibition of necroptosis in one cellular screening assay. Scatter plots of cell growth (amount of nuclei/frame) or nuclear area in relation to
necroptosis-inhibiting capacity are shown. L929sAhFas cells were pre-treated with Tozasertib or its analogues (3 µM) for 0.5 h or 24 h. Next, cells were
left unstimulated or stimulated with mTNF (40 ng/mL) + zVAD.fmk (10 µM) for 3 h. Proliferation, nuclear area and cell death were quantiﬁed by
staining the cells with propidium iodide (PI) (3 µM) and Hoechst (1 µM) for image analysis with BD pathway. Percentage of cell death (% PI-positive
nuclei) was calculated as percent of control (DMSO). d The selection of Tozasertib analogues that inhibited necroptosis was validated in a
ﬂuorometric cell death assay over time using SytoxGreen (SG) (5 µM). L929sAhFas cells were pre-treated with Nec1s, Tozasertib or its analogues (3
µM) for 0.5 h, followed by mTNF (20 ng/mL) stimulation. Signiﬁcance was analysed using repeated measurements data analysis. Data represent mean
values ±S.E.M. (n = 4). * refers to signiﬁcance compared to DMSO, ♦ refers to signiﬁcance compared to Tozasertib. e Ranking of validated Tozasertib
analogues according to their potential to inhibit necroptosis. Nec1s, Tozasertib or its analogues (3 µM) were ranked for two conditions in L929sAhFas
cells: mTNF (20 ng/mL) and mTNF (20 ng/mL) + zVAD.fmk (10 µM)-induced necroptosis, the latter being a sensitising condition for induction of
necroptosis. Cells were stimulated for 7 h with mTNF and 4 h with mTNF + zVAD.fmk. Data represent mean values ±S.E.M. (n = 2). One-way ANOVA
was performed using Tukey correction for multiple comparison (compounds compared to both DMSO control (*) and Tozasertib (♦)). f Heat map of
screening data (b–c). Dose responses were included in the screening (b–c) assay conditions. IC50 values were determined for cell growth (amount of
nuclei/frame), nuclear area and necroptosis protection after 0.5 h or 24 h pre-treated with compound. Hierarchical clustering (row dendrogram using
Ward’s hierarchical clustering method with normalisation using Z-score calculation) of the IC50 values was then applied on these results in order to
create phenotypic clusters and allow SAR analysis of Tozasertib and its analogues (Tibco Spotﬁre software). Selected analogues for further
characterisation are indicated with arrows on the heat map
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results were obtained in mouse L929sAhFas cells stimu-
lated with mTNF+zVAD.fmk, a sensitising necroptotic
condition (Fig. 3e and Supplementary Table 2). Overall,
these data illustrate that Tozasertib targets RIPK1, but not
RIPK3, and that Tozasertib analogues were designed with
increased speciﬁcity for Aurora kinase or RIPK1 as
characterised with human and mouse cellular phenotypes
and with direct inhibition of recombinant kinases.
Discussion
Tozasertib, also known as VX-68034, is a small molecule
type I kinase inhibitor targeting the Aurora family of
serine/threonine protein kinases15. This kinase family is
crucial for proper proliferation and cell cycle progres-
sion3,4,7,35. Increased expression or gene ampliﬁcation of
Aurora A/B has been observed in a number of can-
cers6,8,36,37 and its oncogenic potential has been illustrated
by the fact that Aurora A overexpression induces
transformation of mammalian ﬁbroblasts38. Tozasertib-
induced inhibition of Aurora kinase activity results in cell
proliferation defects, disruption of bipolar spindle for-
mation, polyploidy and ﬁnally cell death3,6,39–43. These
phenotypic parameters are associated with defective
mitosis and cytokinesis. Tozasertib has entered phase I/II
clinical trials for the treatment of solid tumours44, chronic
myeloid leukaemia and acute lymphocytic leukaemia with
T351I BCR-ABL mutations45–47. Although Tozasertib
treatment has clear anti-tumour activity, studies were
discontinued due to toxic adverse effects including febrile
neutropenia, anaemia and thrombocytopenia5,16. Type I
kinase inhibitors are known to have more than one pos-
sible target or binding partner. Also, Tozasertib has been
shown to bind other kinases than Aurora. Other kinase
targets that have been described for Tozasertib are the
oncogenic kinases Flt-3 and Abl (both wild-type Abl
kinase and imatinib-resistant Abl mutant (T315I)) and
Fig. 3 Potency and speciﬁcity ranking of Tozasertib analogues is conﬁrmed by in vitro kinase activity proﬁling and validated in a human
and mouse cell line. a–c An in vitro ADP-Glo kinase assay using recombinant human (h)RIPK1 (100 nM) (a), hAur A kinase (25 nM) (b) or hAur B
kinase (25 nM) (c) was performed. Recombinant protein was incubated with the selected analogues, according to potency and speciﬁcity (selection
indicated), at concentrations as indicated. Also, Nec1s and Tozasertib were included. Data represent mean value ±S.E.M. (n = 2). d Human HT-29 cells
were pre-treated with Nec1s, Tozasertib and the Tozasertib analogues (concentration as indicated) for 1 h, followed by stimulation with hTNF (100
ng/mL) + Tak1i (1 µM) + zVAD.fmk (20 µM) for 17 h. Cells were stained with SytoxGreen (5 µM) and cell death was measured using the FluoStar
ﬂuorescence detection system. e Murine L929sAhFas cells were pre-treated with Nec1s, Tozasertib and the Tozasertib analogues (concentration as
indicated) for 1 h, followed by stimulation with mTNF (20 ng/mL) for 3 h. Percentage cell death (% PI-positive nuclei) was determined as percent of
control. d–e Data represent mean value ±S.E.M. (n = 3)
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JAK 2 kinase, with the latter playing a role in imatinib
resistance in chronic myelogenous leukaemia3,5,14,15,45,48.
Davis et al. performed an interaction study consisting of
72 kinase inhibitors and 442 kinases, covering more than
80% of the human catalytic protein kinome17. This study
showed that Tozasertib binds to RIPK1 with a Kd of 20
nM, suggesting that Tozasertib could inhibit TNF-
induced necroptosis, a RIPK1-dependent path-
way19,21,49,50. In our study, we show that Tozasertib not
only targets Aurora kinases, resulting in proliferation and
cytokinesis defects, but also inhibits TNF-induced
necroptosis and that its potency is similar for both cel-
lular phenotypes. Both in murine (L929sAhFas, MEF
cells) and human (HT-29) cell lines, Tozasertib inhibits
TNF-induced necroptosis at concentrations below 10 µM
(IC50 HT-29 is 0.3 µM and IC50 L929 is 0.7 µM). Tar-
geting the active site of kinases, like the competition of
Tozasertib with ATP for binding to the active site14,51,
remains a challenge due to the fact that ATP-binding
pockets are very similar between kinases14. This speciﬁcity
issue for kinase inhibitors is a.o. illustrated by a recent
report about PERK inhibitors that are also very potent
RIPK1 inhibitors52. Even when sequence identity with
Aurora kinase is less than 50%, which is the case for Flt3
and Abl, kinase inhibition by Tozasertib is still observed3,
indicating that other factors (a.o. structural properties)
may also inﬂuence interaction of the kinases with
Tozasertib.
In order to study the possible relation between Aurora
kinase inhibition and RIPK1-dependent necroptosis
inhibition, other known Aurora kinase inhibitors (AMG-
900, Barasertib, Danusertib, SNS-314 mesylate) were
tested for inhibition of TNF-induced necroptosis. Except
for SNS-314 mesylate, these Aurora kinase inhibitors were
not able to protect against TNF-induced necroptosis,
illustrating that Aurora and necroptosis inhibition are
independent processes. Nec1 and Nec1s were the ﬁrst
RIPK1 inhibitors discovered and are now used in research
as benchmark for RIPK1 inhibition19,49,53,54. Other
necrostatins have also been developed49,55–57, but
although they had proper selectivity, pharmacokinetic
properties of all necrostatins were moderate58. This
indicates the need for better therapeutic RIPK1 inhibitors.
Recently, GSK developed a type II/III RIPK1 inhibitor
(GSK2982772) that is currently in clinical trial phase IIa
for the treatment of psoriasis, rheumatoid arthritis and
ulcerative colitis59,60. Since necrostatins and the GSK
RIPK1 inhibitor are classiﬁed as type II or III kinase
inhibitors, and Tozasertib has structural elements of a
type I kinase inhibitor (targeting the ATP-binding pocket
of the kinase), this created the opportunity to develop type
I RIPK1 inhibitors based on Tozasertib structure.
Therefore, 67 Tozasertib analogues were developed
(Hofmans S. et al, manuscript under review) and tested
for cytokinesis defects and necroptosis protection in order
to design novel type I RIPK1 inhibitors with higher
potency and selectivity than Tozasertib. In a second step,
analogues that inhibited necroptosis were validated using
a real-time ﬂuorometric method33. After detailed analysis
and clustering of IC50 values, Tozasertib analogues were
selected that had increased speciﬁcity for either cytokin-
esis defects (UAMC3033 and UAMC2550) or necroptosis
protection (UAMC3063 and UAMC3064). These selected
Tozasertib analogues have been tested for their potency to
inhibit recombinant kinases Aur A, Aur B and RIPK1.
These data conﬁrmed our observation in the cellular assay
that the selected analogues have similar potency for
Aurora and/or RIPK1, but show increased speciﬁcity.
Although analogues speciﬁc for necroptosis (RIPK1)
inhibition in cellular assays still inhibited recombinant
Aurora kinases, the more than tenfold decrease in potency
is enough to reduce signiﬁcantly the cytokinesis defects in
the cellular assay.
It is not clear how Tozasertib and its analogues bind
RIPK1. Each of the Tozasertib analogues can have a very
different binding and interaction with both Aurora A, B
and RIPK1. Indeed, kinases can have two different con-
formations, the ‘DFG-in’ active conformation and the
‘DFG-out’ inactive conformation61. RIPK1 has a DLG
motif instead of the well-known DFG motif, resulting in
different organisation of the amino acids during catalysis.
Necrostatins (Nec-1a, Nec-3a and Nec-4) can stabilise
RIPK1 in an inactive conformation that has structural
similarities with the inactive conformation of the protein
PKA (with DFG motif)55. Many therapeutic kinase inhi-
bitors bind the closed conformation (Imatinib,
GW572016 and A-770041) by making hydrophobic
interactions with the enzyme14,62–64, but Tozasertib has a
different way to interact with Aurora kinases. Tozasertib
is described as a type I kinase inhibitor that binds at the
ATP site without penetrating the allosteric pocket and
therefore does not depend on speciﬁc kinase conforma-
tion for its binding65,66. Full activation of Aurora A kinase
is only achieved when it binds to its co-factor targeting
protein for Xklp2 (TPX2). Binding of TPX2 causes the
activation loop to fold away from the active site, providing
the DFG-in ‘open’, active kinase conformation67,68. Simi-
lar interaction of Aurora B with its co-factor inner cen-
tromere protein (INCENP) has been described69.
Depending on the presence of the co-factor, Tozasertib
can bind different conformations. Tozasertib was shown
to bind to the closed conformation of Aurora A in the
absence of TPX214,70,71. On the other hand, in the pre-
sence of TPX2 it binds to the open, active conformation of
Aurora A51,67. Tozasertib also binds to the DFG-in ‘open’,
active conformation of the imatinib-resistant form of Abl
kinase containing H396P mutation65. This shows that
prediction of the binding mode of Tozasertib, and
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especially its analogues, to RIPK1 (and Aurora kinase) will
be difﬁcult due to the high ﬂexibility of these kinases
(switching between inactive–active conformations) and
needs further investigation.
Tozasertib is able to reduce tumour growth in vivo in
xenograft models of leukaemia and colon cancer (HL-60
and HCT-116)15. With its clear anti-cancer activity15,39,45
and apoptosis-inducing capacity42,43, it is surprising that it
at the same time inhibits TNF-induced necroptotic cell
death at concentrations below 10 µM. But, Tozasertib is
not the only chemotherapeutic agent that inhibits
necroptosis. Other kinase inhibitors have been described
to inhibit RIPK1 and/or RIPK3: ponatinib72,73, dabrafe-
nib74, pazopanib72 and Sorafenib75. The fact that so many
chemotherapeutic kinase inhibitors have been selected
and turned out to have necroptosis inhibition properties
may suggest that necroptosis targeting paradoxically may
be part of the anti-tumour mechanism. It could also be
that it just reﬂects the high chance for resemblance of
ATP pocket targeting kinase inhibitors, especially small
molecule type I inhibitors designed to insert into the ATP
pocket, a feature that can have high similarity among
kinases. However, the idea that proteins of the core
pathway of necroptotic cell death (RIPK1/3 and MLKL)
can promote tumour growth has been recently pub-
lished22,23,76,77. During necroptosis, the cell explodes and
releases damage-associated molecular patterns
(DAMPs)78. These events may happen in the necrotic
core22. This continuous presence of necrotic dying cells
and the released DAMPs could create a pro-tumorigenic
inﬂammatory environment that enhances the growth of
the tumour mass. This could explain why targeting RIPK1
could contribute to the anti-cancer activities of these
chemotherapeutics. Overall, we show that Tozasertib
directly targets RIPK1 and therefore protects against
TNF-induced necroptosis, and that Tozasertib analogues
were designed with increased speciﬁcity for Aurora
kinases or RIPK1 kinase.
Materials and methods
Cell culture, cytokines and reagents
L929 cells stably transfected with hFas and designated
as L929sAhFas were generated as previously described30.
All L929 cell lines and MEF cells were cultured in DMEM
supplemented with 10% (v/v) FCS and L-glutamine
(0.03%). HT-29 cells were cultured in EMEM medium
supplemented with 10% (v/v) FCS and L-glutamine
(0.03%). Following cytokines were used: recombinant (rec)
human and murine TNF-α were produced at VIB protein
Service Facility (Ghent, Belgium) with a speciﬁc biological
activity of 3× 107 IU/mg and 1.27× 108 IU/mL, respec-
tively. Following reagents were purchased as indicated:
Nec1s (synthesised by the Laboratory of Medicinal
Chemistry; University of Antwerp), GSK’963 (Aobious,
AOB9775, Gloucester, MA), Tozasertib (LC Laboratories,
T-2304), Tozasertib analogues (synthesised by the
Laboratory of Medicinal Chemistry; University of
Antwerp), Tak1 kinase inhibitor NP-009245 (AnalytiCon
Discovery GmbH, Potsdam, Germany), z-VAD-fmk
(Bachem, Bubendorf, Switzerland and R&D systems)
and agonistic anti-human Fas (clone 2R2, Cell Diag-
nostica, Munster, Germany).
Antibodies and immunoblotting
Antibodies used were anti-phospho-Aurora A
(Thr288)/Aurora B (Thr232)/Aurora C (Thr198)
(D13A11) (Cell Signaling, #2914, Danvers, MA, USA),
anti-tubulin-HRP (abcam, ab21058, Cambridge, UK).
After treatments, cells were washed twice with PBS and
lysed with 2× Laemmli buffer directly. These samples
were used for SDS-PAGE and immunoblotting. Tubulin
was used as loading control.
Growth arrest and cell death analysis
Proliferation, cytokinesis defects and cell death were
analysed using a BDPathway 855 high-content screening
instrument (BD Biosciences)31,79. Ten thousand (1 h
assay) or ﬁve thousand (24 h assay) cells were seeded in a
black-clear 96-well plate. The next day, the cells were pre-
treated with the indicated compounds for 1 or 24 h and
then stimulated with mTNF, hTNF or agonistic anti-Fas
Ab (concentration as indicated) in the presence of 3 µM
propidium iodide (Sigma-Aldrich) and 1 µM Hoechst
(Sigma-Aldrich). Per condition, 25 image frames were
taken with a ×20 objective containing a minimum of 1000
cells. Data were analysed using the Columbus software
package (PerkinElmer). The image algorithm identiﬁes
objects as nuclei using the Hoechst channel and cate-
gorises cells as life or dead using the PI channel. The
percentage of PI+ nuclei is calculated as read-out for cell
death. The total number of nuclei after 24 or 48 h treat-
ment reﬂects cell growth and nuclear area/nuclear
roundness are the parameters that measure Aurora kinase
inhibition and therefore growth arrest and cytokinesis
defects. For time kinetics and when indicated, cell death
was analysed on a FLUOSTAR Omega (BMG Labtech,
Offenburg, Germany). Cells were stained with 5 µM
SytoxGreen (Life Technologies) and 33 µM ac-DEVD-
amc (PeptaNova GmbH, Sandhausen, Germany) together
with treatment as indicated. Maximal cell death was
obtained by permeabilizing all cells with Triton X-100
(0.05%). Cell death and caspase activity was determined as
described previously33.
Clonogenic assay
L929sAhFas cells were treated with Tozasertib (con-
centration as indicated) for 24 h. Next, treatment was
removed and 50 cells/condition were seeded. After
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10 days, cells were ﬁxed with 4% PFA for 10 min. After
ﬁxation, cells were stained with a 0.01% crystal violet
solution for 1 h. Cells were washed with PBS, dried
overnight and images were taken. Colonies were counted
using ImageJ.
In vitro ADP-Glo kinase assay
Compounds (concentrations as indicated) were co-
incubated with recombinant hRIPK1 (100 nM) (produced
in our laboratory), hAurora kinase A (25 nM) or hAurora
kinase B (25 nM) (ADP-GloTM kinase assay+Aurora
A/Aurora B kinase enzyme system, Promega, V9081 and
V9181). For hRIPK1, the kinase assay buffer (2×) contains
50mM HEPES pH 7.5, 30mM MgCl2, 50mM NaCl,
0.5mg/mL BSA, 0.02% CHAPS and 1mM DTT. For the
Aurora kinases, the kinase assay buffer was used from
the promega assay (V9081, V9181). Next, the in vitro ADP-
GloTM kinase assay (Promega, V6930) was used to deter-
mine kinase activity. The assay was performed according to
the manufacturer’s protocol. The primary kinase reaction
was carried out for 4 h at room temperature and a 2:2:1
ratio of kinase reaction volume to ADP-Glo reagent volume
to kinase detection reagent volume was used.
Statistics
Two or three independent experiments were performed
(as indicated in Figure legends) and data were analysed
using GraphPad Prism 7 (when indicated). Values repre-
sent the mean values± standard error of the mean, unless
indicated otherwise. IC50 values were calculated using
nonlinear curve ﬁtting (four parameters) with ﬁxed top
and bottom in GraphPad Prism 7 (Table 2). All para-
meters, in which the compounds are inhibitory, are
indicated with IC50 values. Only for nuclear area, the
values indicate EC50, as Tozasertib (and analogues)
enhances nuclear area. The deﬁnition of IC50 and EC50 is
also indicated in the legends of the Tables. When indi-
cated, one-way ANOVA was performed using Tukey
correction for multiple comparison. *p< 0.05, **p< 0.01,
***p< 0.001, ****p< 0.0001, with *, Δ and ♦ referring to
signiﬁcance compared to respectively DMSO control,
Nec-1s and Tozasertib.
Repeated measurements data analysis (FIG1G and FIG2D)
Percentages of cell death were analysed as repeated
measurements using the residual maximum likelihood
(REML) approach as implemented in Genstat v18 (Gen-
stat Reference Manual (Release 18), Part 3 Procedures.
2015. VSN International, Hemel Hempstead, UK). Brieﬂy,
a linear mixed model with compound, time and com-
pound× time interaction as ﬁxed terms, and subject.time
used as residual term, was ﬁtted to data. Times of mea-
surement were set at equal intervals and an autoregressive
correlation structure of order 1 (AR1) with equal
variances across time, was selected as best model ﬁt in all
cases, based on the Aikake information coefﬁcient. Sig-
niﬁcances of the ﬁxed terms and pairwise comparisons of
compounds across time were assessed by an F-test.
Probit analysis
Probit analysis, as implemented in Genstatv18 (Genstat
Reference Manual (Release 18), Part 3 Procedures. 2015.
VSN International, Hemel Hempstead, UK), was used to
model the relationship between the doses of compounds
and the cell death response or kinase activity. Doses were
transformed to logarithms and IC50 values for each
compound were calculated. The dispersion parameter was
ﬁxed to 1 and used when calculating standard errors of
the IC50 values. The signiﬁcance of differences between
EC50 values was assessed on a log-scale using a t test,
before back transforming to the original scale.
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